Reviews/Anti Amyloid Antibodies/Anti-amyloid drugs are disease-modifying
Cme · AMAB-CME-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
The question is whether these two antibody drugs change the underlying course of Alzheimer's disease rather than just easing symptoms. For lecanemab, a large pivotal trial [8] and a real-world study in China [22] both show the drug removes brain amyloid and slows the rate of decline in memory and daily function. For donanemab, the corpus holds a smaller, earlier trial [5] that cleared amyloid and met its main cognitive-function measure, but only narrowly, with mixed results on other measures, and its larger confirmatory trial is not in this evidence set. A real-world European report [1] showed both drugs strongly reduce amyloid but found no measurable cognitive change over its short, small follow-up. The panel judged the biological effect on amyloid to be consistent and the clinical slowing clearest for lecanemab, with donanemab resting on thinner ground.
The pivotal phase 3 lecanemab trial [8] reduced brain amyloid (difference -59.1 centiloids) and produced less decline on the CDR-SB (difference -0.45; 95% CI -0.67 to -0.23; P<0.001), with consistent effects on cognitive, composite and daily-function scales. The phase 2 donanemab trial [5] reduced amyloid by 85.06 centiloids and improved its primary iADRS composite (difference 3.20; 95% CI 0.12 to 6.27; P=0.04), though 'the results for most secondary outcomes showed no substantial difference.' Real-world data confirm amyloid engagement for both: a Chinese multicenter cohort [22] reported lecanemab 'significantly attenuated cognitive decline versus ADNI' with amyloid clearance (mean -22.1 Centiloid), and an Italian cohort [1] showed amyloid dropping a mean -52.4 Centiloids. Biomarker (amyloid) modification is thus the most uniform signal across the primary data. The contested point: The evidence divides on whether amyloid removal amounts to clinical disease modification: the Italian cohort [1] cleared amyloid yet 'cognitive measures showed no significant change', and donanemab's clinical case here rests on a single borderline phase 2 primary [5] (P=0.04) with mixed secondaries and no confirmatory phase 3 in the corpus. There is also disagreement over whether modest scale differences such as the CDR-SB -0.45 in [8] reflect altered disease trajectory or a small symptomatic effect.
All 24 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Anti Amyloid Antibodies, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Donanemab's clinical disease-modification evidence in this corpus is a single phase 2 RCT [5] with a borderline primary result (P=0.04) and explicitly mixed secondary outcomes; the confirmatory phase 3 (TRAILBLAZER-ALZ2) is absent, so the second named drug is materially under-evidenced for the claim.
The real-world Italian cohort [1] showed significant amyloid clearance but no significant cognitive change — demonstrating that biomarker (amyloid) modification is not equivalent to demonstrated clinical disease modification, which is what 'disease-modifying' implies.
Where it remains uncertain. A real-world cohort cleared amyloid but recorded no significant cognitive change [1], and donanemab's confirmatory phase 3 is absent while its phase 2 primary is borderline with mixed secondaries [5].
Aleatory
The Italian cohort reports only 29 treatment courses with 11 at six-month follow-up [1], so random variation can dominate and obscure a true cognitive effect.
Epistemic
Only the phase 2 donanemab trial [5] is in the corpus; its confirmatory phase 3 is absent, so the drug's clinical case cannot be strengthened from this evidence.
The load-bearing papers from a corpus of 24, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Real-world confirmation that both drugs clear amyloid, though this small cohort saw no cognitive change over short follow-up
“Among 11 patients with six-month follow-up, amyloid burden decreased significantly (mean change − 52.4 Centiloids)”
Panel auditInternal validity: low · scope of inference: Feasibility and early safety/biomarker response of both drugs in one European memory clinic.Key limitations: no control arm · very small cohort · short follow-up · cognition unchanged
Phase 2 RCT (N=257) supporting donanemab's disease-modifying clinical signal, with the caveat of mixed secondaries
“At 76 weeks, the reductions in the amyloid plaque level and the global tau load were 85.06 centiloids and 0.01 greater, respectively, with donanemab than with placebo.”
Panel auditInternal validity: medium · scope of inference: Donanemab in early symptomatic AD with tau and amyloid on PET over 76 weeks.Key limitations: phase 2 · modest effect · secondary outcomes mixed · small sample
Pivotal phase 3 RCT (N=1795) establishing lecanemab both clears the disease substrate and slows clinical decline — the two components of disease modification
“The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo (difference, -0.45; 95% confidence interval [CI], -0.67 to -0.23; P<0.001).”
Panel auditInternal validity: high · scope of inference: Lecanemab in early AD (MCI or mild dementia) over 18 months.Key limitations: 18-month duration · adverse events including ARIA · small absolute difference
3 of 24 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Both drugs demonstrably engage the underlying amyloid pathology and slow or improve clinical measures, but donanemab's confirmatory phase 3 is absent and its phase 2 primary is borderline, holding confidence below Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Donanemab confirmatory phase 3 evidence. Donanemab's clinical case here is a single phase 2 with a borderline primary (P=0.04) and mixed secondaries [5]; without confirmatory randomized evidence the second named drug is materially under-supported. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Incorporate or conduct a large, double-blind, placebo-controlled phase 3 trial of donanemab in early Alzheimer's disease reporting cognitive, functional and amyloid endpoints.
Open question: Does donanemab produce a confirmed clinical disease-modifying effect in a phase 3 setting? Why it is still open: The corpus contains only a phase 2 trial with a borderline primary (P=0.04) and mixed secondaries [5]; the confirmatory phase 3 is absent.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19